STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (Nasdaq: VIR) is a prominent immunology company pioneering the use of advanced technological innovations to address some of the globe's most challenging infectious diseases. Combining leading scientific expertise with management prowess, Vir Biotechnology focuses on creating solutions for diseases that currently have inadequate or non-existent treatments.

Vir's core business revolves around leveraging breakthroughs in immune programming to manipulate pathogen-host interactions effectively. The company employs a multi-program, multi-platform approach, guided by rigorous science and driven by significant medical needs. Its technology platforms comprise antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).

The company's product pipeline targets severe infectious diseases, including hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB). Vir's revenue streams come from various sources, including collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir's strategy includes internal development, collaborations, and acquisitions, positioning itself as a leader in the biotech space. Notably, Vir's recent collaboration with Brii Biosciences has led to significant advancements in the pursuit of a functional cure for HBV. Through this partnership, they have achieved Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments targeting HBV and chronic hepatitis D virus (HDV) infections.

The company's latest achievements highlight its focus on developing effective therapeutic regimens for chronic HBV infection, a disease affecting over 254 million people globally. With ongoing clinical trials and a commitment to scientific excellence, Vir Biotechnology is at the forefront of transforming the treatment landscape for infectious diseases.

Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) has announced that it will release its second quarter 2024 financial results on August 1, 2024. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can access the financial results via a press release that will be available on the company's website after market close. The conference call can be accessed through a webcast on Vir's website or by dialing in using the provided toll-free numbers. A recorded version of the call will be available on the website approximately two hours after the event and will be archived for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
conferences earnings
-
Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) has received FDA clearance for its IND application and Fast Track designation for its combination treatment of tobevibart and elebsiran aimed at chronic hepatitis delta infection. The IND clearance follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024. The Phase 2 SOLSTICE trial data showed high rates of virologic response and ALT normalization at 12 and 24 weeks, with complete 24-week data expected in Q4. This Fast Track designation will facilitate the expedited review and development of this promising treatment. Hepatitis delta, considered the most severe form of chronic viral hepatitis by the WHO, affects over 12 million people globally. Vir plans to initiate its ECLIPSE trial soon, which will support potential registration of the treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
-
Rhea-AI Summary

Vir Biotechnology announced promising preliminary phase 2 data from its SOLSTICE trial for hepatitis delta treatment. The study evaluates tobevibart, a monoclonal antibody, and elebsiran, a small interfering RNA, as monotherapy and combination therapy.

Key findings include high virologic response rates and ALT normalization at 12 and 24 weeks. Combination therapy showed 100% virologic response at both 12 and 24 weeks, while tobevibart monotherapy had 73% and 55% at these intervals. Most adverse events were mild and transient without serious occurrences.

Further data will be presented at the EASL Congress 2024, with a conference call scheduled for June 5, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.66%
Tags
none
Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) announced CEO Marianne De Backer will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 12 at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel. The discussion will be webcast live and archived for 30 days on the Vir website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
-
Rhea-AI Summary

Vir Biotechnology announced the appointment of Mark D. Eisner, M.D., M.P.H. as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner brings over 32 years of experience in biotech, with deep expertise in immunology and infectious diseases. He previously held the CMO position at Sonoma Biotherapeutics and FibroGen, and served as Senior Vice President at Genentech, leading late-stage clinical development across multiple therapeutic areas. Dr. Eisner's role at Vir will involve overseeing clinical development programs and contributing to the company's growth by advancing medicines for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.87%
Tags
management
-
Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 9:00 a.m. PT. The meeting will be conducted virtually via live audio webcast. Stockholders of record at the close of business on April 1, 2024, are eligible to attend and vote. Participants can access the meeting through the provided web link using their control number. Online access will begin at 8:45 a.m. PT on the day of the meeting. Vir Biotechnology encourages all stockholders to vote and submit their proxies in advance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences
Rhea-AI Summary

Vir Biotechnology announced that three abstracts focusing on chronic hepatitis delta and hepatitis B will be presented at the EASL Congress 2024 in Milan from June 5-8.

The presentations include new data from the Phase 2 SOLSTICE trial, evaluating the safety and efficacy of tobevibart and elebsiran in chronic hepatitis delta patients.

Key highlights include 12 and 24-week treatment data, as well as 48-week data for a subset of participants.

Additional 24-week data on all 60 participants will be reported in Q4 2024. An investor conference call is scheduled for June 5 to discuss these findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
none
-
Rhea-AI Summary

Vir Biotechnology announced that the European Association for the Study of the Liver (EASL) Congress 2024 has upgraded its Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The presentation will take place on June 8 during the EASL Congress in Milan, Italy, which runs from June 5-8. The company will also host an investor call on June 5 to discuss the new SOLSTICE data, including 12-week and 24-week treatment outcomes. Additional 48-week data on the efficacy and safety of tobevibart and elebsiran will be provided, complementing data shared at the 2023 AASLD Liver Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
-
Rhea-AI Summary

Brii Biosciences announced that the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for two of its investigational therapies: BRII-877 (tobevibart) and BRII-835 (elebsiran). These therapies target hepatitis B virus (HBV) and are supported by extensive Phase 1 and 2 studies. BRII-877 has treated over 350 patients, showing well-tolerated results and significant decreases in HBsAg levels. BRII-835, studied in over 570 patients, demonstrated robust antiviral activity against HBV. These designations bolster Brii Bio’s ongoing efforts to develop functional cures for chronic HBV and HDV infections, enhancing their therapeutic regimens to achieve higher cure rates in broader patient populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
Rhea-AI Summary

Vir Biotechnology provided a corporate update and reported financial results for the first quarter of 2024. They announced the acceptance of late-breaker SOLSTICE data abstract for poster presentation at the EASL Congress 2024, with two additional hepatitis program data readouts on track for the fourth quarter. The company had $1.51 billion in cash, cash equivalents, and investments as of March 31, 2024. Key pipeline programs include Chronic Hepatitis Delta and Chronic Hepatitis B, with abstracts accepted for poster presentation at the EASL Congress 2024. Additionally, the Company is advancing next-generation antibodies using its proprietary platform and expects to file multiple investigational new drug applications within the next 18 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.18%
Tags

FAQ

What is Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. (Nasdaq: VIR) is an immunology company focused on combining advanced technologies to treat and prevent serious infectious diseases, including HBV, influenza A, HIV, and TB.

What are the main focus areas of Vir Biotechnology?

Vir Biotechnology focuses on developing treatments for severe infectious diseases by leveraging antibodies, T cells, innate immunity, and siRNA technology platforms.

How does Vir Biotechnology generate its revenue?

Vir Biotechnology generates revenue through collaborations, contracts, grants, and licenses.

What recent achievements has Vir Biotechnology accomplished?

Vir, in collaboration with Brii Biosciences, has received Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments for HBV and HDV infections.

What diseases are targeted by Vir's product pipeline?

Vir's product pipeline targets hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB).

What is the significance of Vir's collaboration with Brii Biosciences?

The collaboration has led to significant advancements in developing functional cure regimens for HBV, evidenced by their recent Breakthrough Therapy Designations.

How does Vir's technology platform work?

Vir utilizes immune programming to manipulate pathogen-host interactions, employing antibodies, T cells, innate immunity, and siRNA to develop effective treatments.

What are some characteristics of BRII-877 and BRII-835?

BRII-877 is a monoclonal antibody targeting HBV and HDV, while BRII-835 is an siRNA targeting HBV and HDV with enhanced stability and antiviral activity.

How does Vir approach treatment for chronic HBV infection?

Vir is conducting clinical trials and planning multiple combination studies to optimize curative regimens for broader HBV patient populations in partnership with Brii Biosciences.

What impact does Vir aim to have on global infectious disease treatment?

Vir aims to transform the treatment landscape for severe infectious diseases by developing innovative, effective therapeutic options through advanced scientific research and collaborations.

Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

VIR Stock Data

1.36B
136.06M
11.76%
76.24%
5.02%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SAN FRANCISCO